SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (394)11/28/1999 11:45:00 PM
From: RWReeves  Read Replies (1) of 666
 
PB- from a press release by Neorx in August

Have not seen much on them-could they be another serious player?

"Our Pretarget® -Lymphoma study with a conjugate using a commercially available antibody also produced several complete responses, including a patient who had failed a previous marrow transplant," said Dr. Abrams. "Our scientists have now made in bacteria a cost-effective, simplified replacement of that conjugate that looks even better in pre-clinical testing than the molecule that produced the clinical results."

Pretarget technology employs separate injections of targeting antibody and therapeutic agent such as radiation that join where the antibody pre-localized. Conventional antibody targeting, by contrast, links the antibody and the therapeutic agent together prior to injection, thereby imparting the long circulation time of the antibody to the therapeutic. Pretarget has enabled NeoRx's patients to receive 4-5 times the dose of radiation than the conventional approach. In its lymphoma study, less than 10 patients received about three-fold the dose of the conventional agents without reaching a maximum tolerated dose (MTD).

I think they are using a Holmium 166 Beta emitter which might be better than a gamma source and the dosimetry involved.

I'm looking into NERX and their odd preferred-NERXP for the BTFLTAB thread.

RWR
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News